Clinical diabetes mellitus is a syndrome of disordered metabolism with inappropriate hyperglycemia due either to an absolute deficiency of insulin secretion or a reduction in the biologic effectiveness of insulin or both. Type 2 diabetes is primarily the result of poor diet and lack of exercise (unfortunately the lifestyle of many Americans) which leads to obesity and diabetes. The total costs for treatment and care of diagnosed diabetic patients in the United States in 2007 was $174 billion. Type 2 diabetes mellitus accounts for 80-90% of diabetes cases in the United States and is associated with an increased risk for a number of life-threatening complications. These include heart disease and stroke, high blood pressure, blindness, kidney disease, nervous system disease, amputation, and complications of pregnancy and surgery. Probably not coincidentally, all of the above complications are associated with insufficient nitric oxide (NO) production. Endothelial dysfunction with reduced NO generation and bioavailability plays a key role in the pathogenesis of diabetic vascular disease and complications and likely serves as the key link between metabolic disorders and cardiovascular disease. The statistics are staggering.
Heart disease and stroke
• In 2004, heart disease was noted on 68% of diabetes-related death certificates among people aged 65 years or older.
• In 2004, stroke was noted on 16% of diabetes-related death certificates among people aged 65 years or older.
• Adults with diabetes have heart disease death rates about 2 to 4 times higher than adults without diabetes.
• The risk for stroke is 2 to 4 times higher among people with diabetes.Pharmaceutical companies have been attempting to develop drugs around Nitric Oxide for years.
High blood pressure
• In 2003–2004, 75% of adults with self-reported diabetes had blood pressure greater than or equal to 130/80 mmHg, or used prescription medications for hypertension.
• Diabetes is the leading cause of new cases of blindness among adults aged 20–74 years.
• Diabetic retinopathy causes 12,000 to 24,000 new cases of blindness each year.
• Diabetes is the leading cause of kidney failure, accounting for 44% of new cases in 2005.
• In 2005, 46,739 people with diabetes began treatment for end-stage kidney disease in the United States and Puerto Rico.
• In 2005, a total of 178,689 people with end-stage kidney disease due to diabetes were living on chronic dialysis or with a kidney transplant in the United States and Puerto Rico.
Nervous system disease (Neuropathy)
• About 60% to 70% of people with diabetes have mild to severe forms of nervous system damage.
• More than 60% of nontraumatic lower-limb amputations occur in people with diabetes.
• In 2004, about 71,000 nontraumatic lower-limb amputations were performed in people with diabetes.
Cost of Diabetes
$116 billion for direct medical costs
$58 billion for indirect costs (disability, work loss, premature mortality)
After adjusting for population age and sex differences, average medical expenditures among people with diagnosed diabetes were 2.3 times higher than what expenditures would be in the absence of diabetes.
Although we have not conducted any clinical trials directly in diabetic patients, we are getting unsolicited feedback from diabetic patients who have been taking Neo40 for several months, that their fasting glucose is better managed, they have more energy and several have even reduced their anti-diabetic medications. Of course you should consult with your physician before any of these measures are taken.
We have preliminary indication from a small trial in Korea using our Neo40 product in diabetic patients. Neogenis recently shipped Neo40 Daily to a group of Korean physicians that treat chronic diabetes patients – those for whom medication cannot control their glucose levels. The doctors chose ten patients, took a baseline blood draw, then put them on a twice daily regimen of Neo40 Daily. They were instructed not to change anything else in their daily routine. After one week, the patients returned for another blood draw. 100% had at least a 50% decline in their glucose levels. Needless to say, the doctors are ecstatic. As evidence, there was a Korean language layout of our package on our fax machine bright and early the next day!
The fact is that although most FDA approved medications are effective at lowering fasting blood glucose but the cardiovascular side effects are sometimes detrimental . Avandia is the most recent example of such a drug that is very effective at treating diabetes but the increased incidence of heart attack and stroke in patients taking Avandia have cause the FDA to pull from the market. The complications of diabetes as mentioned above are clearly a result of insufficient nitric oxide production. Until we begin to restore NO production or homeostasis in the diabetic population, we will not see any long term benefits of traditional therapies. Neo40 may be the answer to restoring NO homeostasis in diabetic patients. We will keep you posted on the results from our trials.